Synthesis, characterization, and antibacterial evaluation of new alkyl 2-amino-4-aryl-4*H*-chromene-3-carboxylates

Sedighe Gholipour[1], Abolghasem Davoodnia[1]*, Mahboobeh Nakhaei-Moghaddam[2]

[1] *Department of Chemistry, Mashhad Branch, Islamic Azad University,*
  Mashhad 91735-413, Iran;
  e-mail: adavoodnia@mshdiau.ac.ir, adavoodnia@yahoo.com

[2] *Department of Biology, Mashhad Branch, Islamic Azad University,*
  Mashhad 91735-413, Iran; e-mail: m.nakhaei@mshdiau.ac.ir

A series of alkyl 2-amino-4-aryl-4*H*-chromene-3-carboxylates was synthesized by an efficient, solvent-free one-pot three-component cyclocondensation of resorcinol, aromatic aldehydes, and ethyl or methyl cyanoacetate using sodium carbonate as catalyst. The present methodology offers several advantages, such as a simple procedure with ease of handling, short reaction time, high yields, and the absence of any volatile and hazardous organic solvents. The products were characterized on the basis of IR, ^{1}H NMR, and ^{13}C NMR spectral and microanalytical data and evaluated for their antibacterial activity against Gram-positive bacteria (*Staphylococcus epidermidis* and *Staphylococcus aureus*) and Gram-negative bacteria (*Escherichia coli*) using paper disc diffusion technique.

Keywords: alkyl 2-amino-4-aryl-4*H*-chromene-3-carboxylates, ethyl cyanoacetate, methyl cyanoacetate, sodium carbonate, antibacterial activity, cyclocondensation.

The chromene moiety has emerged as a privileged scaffold for drug design and discovery and generated great attention because of certain natural and synthetic chromene derivatives possess important biological properties such as antitumor,[1] antiviral,[2] antivascular,[3] antimicrobial,[4] antihypertensive,[5] anticonvulsant,[6] and TNF-α inhibitor activity.[7] They have also been widely employed as cosmetics, pigments,[8] and potent biodegradable agrochemicals.[9] 7-Hydroxy-6-methoxy-4*H*-chromene **I** (Fig. 1) is an example of naturally occurring 4*H*-chromene, which was obtained from the

flowers of *Wisteria sinensis* and is one of their fragrance components.[10] Among different types of chromene systems, 2-amino-4*H*-chromenes have been reported to exhibit highly useful proapoptotic properties for the treatment of a wide range of cancer ailments.[11] In cancer chemotherapy, 2-amino-4*H*-chromene **II** was marked for drug development due to its high inhibition of tumor-associated Bcl-2 proteins.[12] A modified 4*H*-chromene structure **III** was able to induce apoptosis (programmed cell death) in several cancer cell lines.[13] 2-Amino-4*H*-chromenes have also been shown to exhibit antibacterial[14–16] and antifungal[16] activity.

Due to the aforementioned important properties of chromene derivatives, considerable attention has been focused on the development of environmentally friendly methodologies for the synthesis of 2-amino-4*H*-chromene scaffold. Several methods have been reported for the synthesis of 2-amino-4*H*-chromene-3-carbonitriles such as potassium carbonate-catalyzed conjugate addition-cyclization reaction of malononitrile with Knoevenagel adducts, previously formed from salicylaldehyde, and a range of nucleophiles, such as oxindole, pyrazolone, nitromethane, *N,N*-dimethylbarbituric acid, or indanedione;[17] one-pot reaction of salicylaldehyde, malononitrile, and nitroalkanes catalyzed by DBU;[18] reaction of various


Figure 1. Structures of some biologically active 4*H*-chromenes.

In conclusion, we have reported a convenient method for the synthesis of some new alkyl 2-amino-4-aryl-4*H*-resorcinols with benzylidene malononitriles using various bases as catalyst;[19–21] reaction of malononitrile with *in situ* generated sensitive *ortho*-quinone methides from 2-(aryl-sulfonyl)alkyl phenols;[22] reaction of malononitrile with photochemically generated *ortho*-quinone methides from *o*-(dimethylaminomethyl)phenols or *o*-(hydroxymethyl)-phenols;[23] or stepwise condensation of salicylaldehydes with 3 equiv of malononitrile.[21] An improved method has also been reported for the synthesis of 2-amino-4-aryl-4*H*-chromene-3-carbonitriles *via* a one-pot three-component cyclocondensation of resorcinol, an aromatic aldehyde, and malononitrile in the presence of various catalysts.[24–31] Despite the availability of a wide variety of synthetic routes toward 2-amino-4*H*-chromene-3-carbonitriles, a closer look at the literature disclosed that the synthesis of alkyl 2-amino-4-aryl-4*H*-chromene-3-carboxylates has been largely overlooked and only a few examples of the synthesis of ethyl 2-amino-4-aryl-4*H*-chromene-3-carboxylates have been reported by stepwise reaction of an aromatic aldehyde and ethyl cyanoacetate followed by cyclization with activated phenols or resorcinol in the presence of piperidine as catalyst after refluxing for several hours in ethanol.[32,33]

Inspired by these facts and due to our interest in the synthesis of heterocyclic compounds with potential biolo-gical activities,[34–38] we report here our results from an efficient solvent-free synthesis of alkyl 2-amino-4-aryl-4*H*-chromene-3-carboxylates by one-pot, three-component cyclocondensation reaction of resorcinol, aromatic aldehydes, and ethyl or methyl cyanoacetate using Na_2CO_3 as catalyst. The products were also evaluated for their antibacterial activity against *Staphylococcus epidermidis* (*S. epidermidis*) ATCC 12228 and *Staphylococcus aureus* (*S. aureus*) ATCC 6538 as Gram-positive and *Escherichia coli* (*E. coli*) ATCC 8739 as Gram-negative bacteria using paper disc diffusion technique.

At first, the synthesis of compound **4a** was selected as a model reaction to optimize the reaction conditions. The reaction was carried out by heating equimolar amounts of resorcinol (**1**), benzaldehyde (**2a**), and ethyl cyanoacetate (**3a**) under various conditions. We decided to investigate the efficiency of Na_2CO_3 in the model reaction under solvent-free conditions, which offers several advantages such as being environmentally friendly, simpler work-ups, cleaner products, enhanced selectivity, reduction of by-products, and faster reactions. To find the optimum reaction conditions, different parameters were studied for the formation of compound **4a**. The results are summarized in Table 1. Low yield of the product was obtained in the absence of the catalyst by heating the reaction mixture at 110°C under solvent-free conditions for 120 min (entry 1). This results indicate that the catalyst is necessary for the reaction. We were pleased to see that the reaction was efficiently catalyzed by Na_2CO_3 under solvent-free conditions at elevated temperature leading to product **4a** in high yield (entry 2). Then the reaction was performed in the presence of various amounts of the catalyst and also at different temperatures under solvent-free conditions. As

Table 1. Optimization of the reaction conditions for the synthesis of compound **4a** catalyzed by Na_2CO_3

Entry	Na_2CO_3, mol %	Solvent	T, °C	Time, min	Yield, %
1	–	–	110	120	30
2	5	–	80	40	60
3	5	–	110	35	70
4	5	–	140	35	70
5	10	–	80	35	65
6	10	–	110	30	75
7	10	–	140	30	74
8	15	–	80	30	70
9	15	–	110	30	82
10	15	–	140	25	80
11	20	–	80	25	84
12	20	–	110	20	95
13	20	–	140	20	94
14	25	–	110	30	94
15	20	H_2O	Reflux	60	50
16	20	MeOH	Reflux	35	85
17	20	EtOH	Reflux	35	80
18	20	$MeCO_2Et$	Reflux	40	78
19	20	CH_2Cl_2	Reflux	45	72

can be seen, the efficiency of the reaction is affected mainly by the amount of Na_2CO_3 and reaction temperature. The best result was obtained when the reaction was run at 110°C in the presence of 20 mol % of Na_2CO_3 (entry 12). For showing the effect of solvent, the same model reaction was also carried out in different solvents including H_2O, MeOH, EtOH, $MeCO_2Et$, and CH_2Cl_2 in the presence of 20 mol % of the catalyst (entries 15–19). As shown, the yield of the product **4a** under solvent-free conditions was greater and the reaction time was considerably shorter than with the conventional methods. Therefore, our optimized conditions are 20 mol % of Na_2CO_3 at 110°C under solvent-free conditions. All subsequent reactions were carried out using these conditions.

Encouraged by the remarkable results obtained in the model reaction and to show the generality and scope of this protocol, a range of alkyl 2-amino-4-aryl-4*H*-chromene-3-carboxylates **4a–j** were prepared by the reaction of resor-cinol (**1**), aromatic aldehydes **2a–g**, and ethyl or methyl cyanoacetate **3a,b** in the presence of Na_2CO_3 under the optimized reaction conditions. The results are summarized in Table 2. As shown, all reactions proceed very cleanly to give the corresponding products **4a–j** in high yields over

Table 2. Synthesis of alkyl 2-amino-4-aryl-4*H*-chromene-3-carboxylates **4a–j** using Na$_2$CO$_3$ as catalyst*

Entry	Product	Ar	R	Time, min	Yield, %	Melting point, °C	
						Found	Reported
1	**4a**	Ph	Et	20	95	217–219	219–221[32]
2	**4b**	Ph	Me	15	98	230–231	–
3	**4c**	4-ClC$_6$H$_4$	Et	20	90	218–220	–
4	**4d**	4-ClC$_6$H$_4$	Me	15	92	227–229	–
5	**4e**	4-BrC$_6$H$_4$	Et	15	90	219–221	–
6	**4f**	4-BrC$_6$H$_4$	Me	15	90	228–229	–
7	**4g**	4-FC$_6$H$_4$	Et	10	95	211–213	–
8	**4h**	2-ClC$_6$H$_4$	Me	20	95	191–192	–
9	**4i**	4-MeOC$_6$H$_4$	Et	20	90	197–199	191–194[32]
10	**4j**	3-BrC$_6$H$_4$	Me	20	95	232–234	–

* Reaction conditions: resorcinol (**1**) (1 mmol), aromatic aldehyde **2a–g** (1 mmol), ethyl or methyl cyanoacetate **3a,b** (1 mmol), and anhydrous Na$_2$CO$_3$ (0.20 mmol, 20 mol %), 110°C, solvent-free.

short reaction times. According to ^{1}H NMR spectral data in aromatic region of chromene ring, resorcinol (**1**) reacts at position C-4 instead of position C-2 because of the steric hindrance between two hydroxyl groups or crowding of the aryl group with the remaining OH group in the product, and therefore 7-hydroxy-4*H*-chromenes **4a–j** are formed not the corresponding 5-hydroxy isomers **5**.[25–30]

The structure of all products **4a–j** was deduced from their spectral and microanalytical data. For example, the ^{1}H NMR spectrum of compound **4f** in DMSO-d_6 showed two sharp singlets at 3.50 and 4.80 ppm for methoxy and methine groups, respectively, along with a signal at 7.62 ppm for the NH$_2$ group, a signal at 9.62 ppm for the OH proton, as well as the signals in the aromatic region due to seven aromatic protons indicating the formation of compound **4f**. The IR spectrum showed absorption bands at 3423, 3308, and 3240 cm^{-1} for NH$_2$ and OH groups. Further proof came from ^{13}C NMR spectrum which showed the characteristic signals at 50.9, 76.4, and 169.0 ppm for methoxy, methine, and carbonyl groups, respectively, as well as other signals in the aromatic region. This compound also gave satisfactory microanalytical data corresponding to the molecular formula C$_{17}$H$_{14}$BrNO$_4$.

The synthesized compounds **4a–j** were screened for the antibacterial activity against reference strains of *S. epidermidis*, *S. aureus*, and *E. coli* bacteria. None of the compounds had inhibition zone at a concentration of 2 mg/disc. The results, as shown in Table 3, revealed that compounds **4a–c** and **4f** are relatively effective against *S. epidermidis* at concentrations ≥ 3 mg/disc, while compounds **4c**, **4g**, and **4j** show weak antibacterial activity against *E. coli* only at a concentration of 4 mg/disc. The minimum inhibitory concentration was 3 mg/disc for compounds **4a–c** and **4f** against *S. epidermidis* and 4 mg/disc for compounds **4c,g,j** against *E. coli*. None

Table 3. Antibacterial evaluation of compounds **4a–j** using disc diffusion method

Compound	Inhibition zone, mm*	
	S. epidermidis	*E. coli*
4a**	6.7 ± 0.2	6.0 ± 0.0
4b**	7.0 ± 0.6	6.0 ± 0.0
4c**	7.0 ± 0.0	6.0 ± 0.0
4d**	6.0 ± 0.0	6.0 ± 0.0
4e**	6.0 ± 0.0	6.0 ± 0.0
4f**	7.3 ± 0.2	6.0 ± 0.0
4g**	6.0 ± 0.0	6.0 ± 0.0
4h**	6.0 ± 0.0	6.0 ± 0.0
4i**	6.0 ± 0.0	6.0 ± 0.0
4j**	6.0 ± 0.0	6.0 ± 0.0
4a***	7.7 ± 0.2	6.0 ± 0.0
4b***	8.0 ± 0.0	6.0 ± 0.0
4c***	7.7 ± 0.2	7.0 ± 0.0
4d***	6.0 ± 0.0	6.0 ± 0.0
4e***	7.3 ± 0.2	6.0 ± 0.0
4f***	7.7 ± 0.2	6.0 ± 0.0
4g***	7.3 ± 0.2	6.7 ± 0.2
4h***	6.0 ± 0.0	6.0 ± 0.0
4i***	6.0 ± 0.0	6.0 ± 0.0
4j***	7.3 ± 0.2	7.0 ± 0.0
DMSO	6.0 ± 0.0	6.0 ± 0.0
Gentamicin	30.3 ± 0.5	20.3 ± 0.5

* Diameter of each disc was 6.0 mm.
** Concentration 3 mg/disc.
*** Concentration 4 mg/disc.

of the compounds showed antibacterial activity against *S. aureus* at concentration of 3 or 4 mg/disc.

In conclusion, we have reported a convenient method for the synthesis of some new alkyl 2-amino-4-aryl-4*H*-chromene-3-carboxylates by one-pot three-component cyclocondensation of resorcinol, aromatic aldehydes, and ethyl or methyl cyanoacetate using sodium carbonate as catalyst under solvent-free conditions. The method offers several significant advantages, including short reaction times, high yields of products, easy work-up, and the absence of any hazardous organic solvents. Some of the synthesized compounds have weak growth-inhibiting effects on *S. epidermidis* and *E. coli*.

Experimental

IR spectra were obtained with KBr pellets using a Tensor 27 Bruker spectrophotometer. ^{1}H and ^{13}C NMR spectra were recorded on a Bruker 400 FT spectrometer (400 and 100 MHz, respectively) in DMSO-d_6 using TMS as internal standard. Elemental analysis was performed on a Thermo Finnigan Flash EA microanalyzer. Melting points were recorded on a Stuart SMP3 melting point apparatus. All chemicals were purchased from Merck and Aldrich and used without additional purification.

Synthesis of alkyl 2-amino-4-aryl-4*H*-chromene-3-carboxylates 4a–j (General method). A mixture of resorcinol (**1**) (0.11 g, 1.0 mmol), an aromatic aldehyde **2a–g** (1.0 mmol), ethyl or methyl cyanoacetate **3a,b** (1.0 mmol) and anhydrous Na$_2$CO$_3$ (0.2 mmol, 20 mol %) was heated in an oil bath at 110°C for 10–20 min. After completion of the transformation (TLC control, eluent ethyl acetate–*n*-hexane), the reaction mixture was cooled to room temperature and warm water was added. This resulted in the precipitation of the product, which was collected by filtration. The crude product was washed with warm water repeatedly and recrystallized from EtOH to give compounds **4a–j** in high yields.

Ethyl 2-amino-7-hydroxy-4-phenyl-4*H*-chromene-3-carboxylate (4a). Yield 95%. IR spectrum, ν, cm^{-1}: 3438, 3372, and 3323 (NH$_2$ and OH), 1666 (C=O). ^{1}H NMR spectrum, δ, ppm (*J*, Hz): 1.01 (3H, t, *J* = 6.4, CH$_3$); 3.90 (2H, q, *J* = 6.4, OCH$_2$); 4.75 (1H, s, CH); 6.40 (1H, s, H-8); 6.43 (1H, d, *J* = 8.0, H-6); 6.94 (1H, d, *J* = 8.0, H-5); 7.02–7.25 (5H, m, H Ar); 7.57 (2H, br. s, NH$_2$); 9.60 (1H, s, OH). ^{13}C NMR spectrum, δ, ppm: 15.8; 60.1; 78.2; 103.7; 113.7; 113.8; 118.3; 127.3; 128.5; 129.7; 131.4; 150.2; 150.6; 158.3; 162.6; 170.0. Found, %: C 69.47; H 5.48; N 4.53. C$_{18}$H$_{17}$NO$_4$. Calculated, %: C 69.44; H 5.50; N 4.50.

Methyl 2-amino-7-hydroxy-4-phenyl-4*H*-chromene-3-carboxylate (4b). Yield 98%. IR spectrum, ν, cm^{-1}: 3418, 3306, and 3227 (NH$_2$ and OH), 1664 (C=O). ^{1}H NMR spectrum, δ, ppm (*J*, Hz): 3.49 (3H, s, OCH$_3$); 4.79 (1H, s, CH); 6.43 (1H, d, *J* = 2.0, H-8); 6.47 (1H, dd, *J* = 8.3, *J* = 2.0, H-6); 6.99 (1H, d, *J* = 8.3, H-5); 7.08 (1H, t, *J* = 7.2, H Ar); 7.14 (2H, d, *J* = 7.3, H Ar); 7.20 (2H, t, *J* = 7.6, H Ar); 7.60 (2H, br. s, NH$_2$); 9.60 (1H, s, OH). ^{13}C NMR spectrum, δ, ppm: 50.4; 76.3; 102.0; 112.0; 116.9; 125.7; 126.7; 128.2; 129.6; 148.4; 149.1; 156.7;

161.1; 161.2; 168.6. Found, %: C 68.72; H 5.11; N 4.67. C$_{17}$H$_{15}$NO$_4$. Calculated, %: C 68.68; H 5.09; N 4.71.

Ethyl 2-amino-4-(4-chlorophenyl)-7-hydroxy-4*H*-chromene-3-carboxylate (4c). Yield 90%. IR spectrum, ν, cm^{-1}: 3417, 3303, and 3247 (NH$_2$ and OH), 1661 (C=O). ^{1}H NMR spectrum, δ, ppm (*J*, Hz): 1.03 (3H, t, *J* = 7.2, CH$_3$); 3.92 (2H, q, *J* = 7.2, OCH$_2$); 4.78 (1H, s, CH); 6.42 (1H, d, *J* = 2.0, H-8); 6.45 (1H, dd, *J* = 8.0, *J* = 2.0, H-6); 6.94 (1H, d, *J* = 8.0, H-5); 7.13 (2H, d, *J* = 8.4, H Ar); 7.25 (2H, d, *J* = 8.4, H Ar); 7.62 (2H, br. s, NH$_2$); 9.67 (1H, s, OH). ^{13}C NMR spectrum, δ, ppm: 15.9; 60.2; 77.7; 103.7; 113.3; 113.8; 117.7; 129.7; 130.4; 131.4; 131.8; 149.3; 150.4; 158.5; 162.5; 170.0. Found, %: C 62.49; H 4.63; N 4.09. C$_{18}$H$_{16}$ClNO$_4$. Calculated, %: C 62.52; H 4.66; N 4.05.

Methyl 2-amino-4-(4-chlorophenyl)-7-hydroxy-4*H*-chromene-3-carboxylate (4d). Yield 92%. IR spectrum, ν, cm^{-1}: 3417, 3376, and 3320 (NH$_2$ and OH), 1666 (C=O). ^{1}H NMR spectrum, δ, ppm (*J*, Hz): 3.48 (3H, s, OCH$_3$); 4.80 (1H, s, CH); 6.42 (1H, d, *J* = 1.6, H-8); 6.46 (1H, d, *J* = 8.4, H-6); 6.98 (1H, d, *J* = 8.4, H-5); 7.14 (2H, d, *J* = 8.4, H Ar); 7.25 (2H, d, *J* = 8.4, H Ar); 7.63 (2H, br. s, NH$_2$); 9.63 (1H, s, OH). ^{13}C NMR spectrum, δ, ppm: 50.9; 76.8; 102.6; 112.6; 117.3; 126.2; 127.1; 127.2; 128.7; 130.1; 149.0; 149.6; 157.3; 161.7; 169.2. Found, %: C 61.56; H 4.23; N 4.19. C$_{17}$H$_{14}$ClNO$_4$. Calculated, %: C 61.55; H 4.25; N 4.22.

Ethyl 2-amino-4-(4-bromophenyl)-7-hydroxy-4*H*-chromene-3-carboxylate (4e). Yield 90%. IR spectrum, ν, cm^{-1}: 3416, 3303, and 3244 (NH$_2$ and OH), 1661 (C=O). ^{1}H NMR spectrum, δ, ppm (*J*, Hz): 1.03 (3H, t, *J* = 6.8, CH$_3$); 3.92 (2H, q, *J* = 6.8, OCH$_2$); 4.77 (1H, s, CH); 6.42 (1H, s, H-8); 6.46 (1H, d, *J* = 8.4, H-6); 6.94 (1H, d, *J* = 8.4, H-5); 7.08 (2H, d, *J* = 8.0, H Ar); 7.38 (2H, d, *J* = 8.0, H Ar); 7.61 (2H, br. s, NH$_2$); 9.64 (1H, s, OH). ^{13}C NMR spectrum, δ, ppm: 15.9; 60.2; 77.6; 103.7; 112.5; 113.8; 117.6; 120.3; 130.8; 131.5; 132.6; 149.7; 150.6; 158.5; 162.6; 169.8. Found, %: C 55.44; H 4.18; N 3.60. C$_{18}$H$_{16}$BrNO$_4$. Calculated, %: C 55.40; H 4.13; N 3.59.

Methyl 2-amino-4-(4-bromophenyl)-7-hydroxy-4*H*-chromene-3-carboxylate (4f). Yield 90%. IR spectrum, ν, cm^{-1}: 3423, 3308, and 3240 (NH$_2$ and OH), 1662 (C=O). ^{1}H NMR spectrum, δ, ppm (*J*, Hz): 3.50 (3H, s, OCH$_3$); 4.80 (1H, s, CH); 6.44 (1H, d, *J* = 2.4, H-8); 6.48 (1H, dd, *J* = 8.4, *J* = 2.4, H-6); 6.99 (1H, d, *J* = 8.4, H-5); 7.10 (2H, d, *J* = 8.4, H Ar); 7.40 (2H, d, *J* = 8.4, H Ar); 7.62 (2H, br. s, NH$_2$); 9.62 (1H, s, OH). ^{13}C NMR spectrum, δ, ppm: 50.9; 76.4; 102.6; 112.7; 116.7; 119.2; 129.5; 130.2; 131.6 (2C); 148.4; 149.5; 157.4; 161.6; 169.0. Found, %: C 54.32; H 3.74; N 3.69. C$_{17}$H$_{14}$BrNO$_4$. Calculated, %: C 54.28; H 3.75; N 3.72.

Ethyl 2-amino-4-(4-fluorophenyl)-7-hydroxy-4*H*-chromene-3-carboxylate (4g). Yield 95%. IR spectrum, ν, cm^{-1}: 3417, 3304, and 3244 (NH$_2$ and OH), 1662 (C=O). ^{1}H NMR spectrum, δ, ppm (*J*, Hz): 1.03 (3H, t, *J* = 6.8, CH$_3$); 3.93 (2H, q, *J* = 6.8, OCH$_2$); 4.79 (1H, s, CH); 6.42 (1H, s, H-8); 6.46 (1H, d, *J* = 8.4, H-6); 6.94 (1H, d, *J* = 8.4, H-5); 7.01 (2H, t, *J* = 8.4, H Ar); 7.14 (2H, t, *J* = 7.2, H Ar); 7.61 (2H, br. s, NH$_2$); 9.66 (1H, s, OH). ^{13}C NMR spectrum, δ, ppm: 15.8; 60.2; 78.1; 103.7; 113.8;

116.2; 116.4; 118.0; 130.3; 131.4; 146.5; 150.6; 158.4; 160.8; 162.5; 169.9. Found, %: C 65.62; H 4.95; N 4.27. $C_{18}H_{16}FNO_4$. Calculated, %: C 65.65; H 4.90; N 4.25.

Methyl 2-amino-4-(2-chlorophenyl)-7-hydroxy-4*H*-chromene-3-carboxylate (4h). Yield 95%. IR spectrum, ν, cm^{-1}: 3427, 3385, and 3315 (NH$_2$ and OH), 1670 (C=O). ^{1}H NMR spectrum, δ, ppm (*J*, Hz): 3.40 (3H, s, OCH$_3$); 5.32 (1H, s, CH); 6.40 (1H, s, H-8); 6.43 (1H, d, *J* = 8.4, H-6); 6.95 (1H, d, *J* = 8.4, H-5); 7.00–7.35 (4H, m, H Ar); 7.66 (2H, br. s, NH$_2$); 9.66 (1H, s, OH). ^{13}C NMR spectrum, δ, ppm: 52.0; 76.9; 103.8; 113.9; 117.2; 129.0; 129.1; 130.6; 130.8; 131.3; 131.4; 132.7; 147.4; 150.4; 158.6; 162.8; 170.0. Found, %: C 61.61; H 4.26; N 4.18. $C_{17}H_{14}ClNO_4$. Calculated, %: C 61.55; H 4.25; N 4.22.

Ethyl 2-amino-7-hydroxy-4-(4-methoxyphenyl)-4*H*-chromene-3-carboxylate (4i). Yield 90%. IR spectrum, ν, cm^{-1}: 3418, 3305, and 3243 (NH$_2$ and OH), 1660 (C=O). ^{1}H NMR spectrum, δ, ppm (*J*, Hz): 1.08 (3H, t, *J* = 6.8, CH$_3$); 3.68 (3H, s, OCH$_3$); 3.96 (2H, q, *J* = 6.8, OCH$_2$); 4.74 (1H, s, CH); 6.44 (1H, s, H-8); 6.48 (1H, d, *J* = 8.4, H-6); 6.78 (2H, d, *J* = 8.4, H Ar); 6.96 (1H, d, *J* = 8.4, H-5); 7.05 (2H, d, *J* = 8.4, H Ar); 7.55 (2H, br. s, NH$_2$); 9.61 (1H, s, OH). ^{13}C NMR spectrum, δ, ppm: 15.9; 56.5; 60.1; 78.4; 103.6; 113.6 (2C); 115.0; 118.7; 129.4; 131.4; 142.4; 150.6; 158.2; 158.7; 162.5; 170.0. Found, %: C 66.84; H 5.57; N 4.12. $C_{19}H_{19}NO_5$. Calculated, %: C 66.85; H 5.61; N 4.10.

Methyl 2-amino-4-(3-bromophenyl)-7-hydroxy-4*H*-chromene-3-carboxylate (4j). Yield 95%. IR spectrum, ν, cm^{-1}: 3415, 3303, and 3261 (NH$_2$ and OH) 1663 (C=O). ^{1}H NMR spectrum, δ, ppm (*J*, Hz): 3.49 (3H, s, OCH$_3$); 4.81 (1H, s, CH); 6.43 (1H, s, H-8); 6.48 (1H, d, *J* = 8.4, H-6); 7.02 (1H, d, *J* = 8.4, H-5); 7.12–7.35 (4H, m, H Ar); 7.65 (2H, br. s, NH$_2$); 9.65 (1H, s, OH). ^{13}C NMR spectrum, δ, ppm: 52.1; 77.3; 103.8; 113.9; 117.7; 123.1; 127.5; 130.3; 131.0; 131.3; 132.1; 150.6; 152.8; 158.6; 162.8; 162.9; 170.0. Found, %: C 54.30; H 3.77; N 3.69. $C_{17}H_{14}BrNO_4$. Calculated, %: C 54.28; H 3.75; N 3.72.

Antibacterial activity. The antibacterial activity of the synthesized compounds was examined against *S. epidermidis* ATCC 12228 and *S. aureus* ATCC 6538 as Gram-positive and *E. coli* ATCC 8793 as Gram-negative bacteria using disc diffusion method according to Kirby–Bauer standards.[39] Suspensions of the tested bacteria were prepared with turbidity equivalent to McFarland tube No. 0.5 (10^7–10^8 CFU/ml). Standard blank discs, containing 2, 3, and 4 mg of the synthesized compounds, were prepared using DMSO as solvent and placed on a Mueller–Hinton agar pre-inoculated with 0.1 ml of bacterial suspension. Discs of gentamicin 10 μg/disc and DMSO were used as positive and negative controls, respectively. All discs were fully dried before the application on bacterial lawn. Plates were incubated for 18–24 h at 37°C, aerobically, and the diameter of inhibitory zones around the discs was measured in millimeter. All determinations were performed in triplicate, and average value was reported as the inhibition zone (mean ± SEM). Minimum inhibitory concentration was defined as the lowest concentration of compound that inhibited the growth of bacteria.

References

1. Raj, T.; Bhatia, R. K.; Sharma, M.; Saxena, A.; Ishar, M. *Eur. J. Med. Chem.* **2010**, *45*, 790.
2. Conti, C.; Monaco, L. P.; Desideri, N. *Bioorg. Med. Chem.* **2014**, *22*, 1201.
3. Gourdeau, H.; Leblond, L.; Hamelin, B.; Desputeau, C.; Dong, K.; Kianicka, I.; Custeau, D.; Boudreau, C.; Geerts, L.; Cai, S.-X.; Drewe, J.; Labrecque, D.; Kasibhatla, S.; Tseng, B. *Mol. Can. Ther.* **2004**, *3*, 1375.
4. Ashok, D.; Lakshmi1, B. V.; Ravi, S.; Ganesh, A.; Adam, S. *Chem. Heterocycl. Compd.* **2015**, *51*, 462. [*Khim Geterotsikl. Soedin.* **2015**, 462.]
5. Johannes, C. W.; Visser, M. S.; Weatherhead, G. S.; Hoveyda, A. H. *J. Am. Chem. Soc.* **1998**, *120*, 8340.
6. Bhat, M. A.; Siddiqui, N.; Khan, S. A. *Acta Pol. Pharm.* **2008**, *65*, 235.
7. Cheng, J.-F.; Ishikawa, A.; Ono, Y.; Arrhenius, T.; Nadzan, A. *Bioorg. Med. Chem. Lett.* **2003**, *13*, 3647.
8. Ellis, G. In *The Chemistry of Heterocyclic of Compounds. Chromenes, Chromanes and Chromones*; Weissberger, A., Taylor, EC, Eds.; John Wiley: New York, 1977., Chapter II, p. 11.
9. Hafez, E. A. A.; Elnagdi, M. H.; Elagamey, A. G. A.; El-Taweel, F. M. A. A. *Heterocycles* **1987**, *26*, 903.
10. Joulain, D.; Tabacchi, R. *Phytochemistry* **1994**, *37*, 1769.
11. Nolan, K. A.; Zhao, H.; Faulder, P. F.; Frenkel, A. D.; Timson, D. J.; Siegel, D.; Ross, D.; Burke Jr, T. R.; Stratford, I. J.; Bryce, R. A. *J. Med. Chem.* **2007**, *50*, 6316.
12. Doshi, J. M.; Tian, D.; Xing, C. *J. Med. Chem.* **2006**, *49*, 7731.
13. Kemnitzer, W.; Drewe, J.; Jiang, S.; Zhang, H.; Crogan-Grundy, C.; Labreque, D.; Bubenick, M.; Attardo, G.; Denis, R.; Lamothe, S.; Gourdeau, H.; Tseng, B.; Kasibhatla, S.; Cai, S. X. *J. Med. Chem.* **2008**, *51*, 417.
14. Zhang, G.; Zhang, Y.; Yan, J.; Chen, R.; Wang, S.; Ma, Y.; Wang, R. *J. Org. Chem.* **2012**, *77*, 878.
15. Kidwai, M.; Saxena, S.; Rahman Khan, M. K.; Thukral, S. S. *Bioorg. Med. Chem. Lett.* **2005**, *15*, 4295.
16. Shah, N. K.; Shah, N. M.; Patel, M. P.; Patel, R. G. *J. Chem. Sci.* **2013**, *125*, 525.
17. He, Y.; Hu, R.; Tong, R.; Li, F.; Shi, J.; Zhang, M. *Molecules* **2014**, *19*, 19253.
18. Zonouzi, A.; Mirzazadeh, R.; Safavi, M.; Ardestani, S. K.; Emami, S.; Foroumadi, A. *Iranian J. Pharm. Res.* **2013**, *12*, 679.
19. Mohammed, F. K.; Soliman, A. Y.; Ssawy, A.; Badre, M. G. *J. Chem. Pharm. Res.* **2009**, *1*, 213.
20. Kolla, S. R.; Lee, Y. R. *Tetrahedron* **2011**, *67*, 8271.
21. Anderson, D. R.; Hegde, S.; Reinhard, E.; Gomez, L.; Vernier, W. F.; Lee, L.; Liu, S.; Sambandam, A.; Snider, P. A.; Masih, L. *Bioorg. Med. Chem. Lett.* **2005**, *15*, 1587.
22. Caruana, L.; Mondatori, M.; Corti, V.; Morales, S.; Mazzanti, A.; Fochi, M.; Bernardi, L. *Chem.–Eur. J.* **2015**, *21*, 6037.
23. Fujiwara, M.; Sakamoto, M.; Komeyama, K.; Yoshida, H.; Takaki, K. *J. Heterocycl. Chem.* **2015**, *52*, 59.
24. Khaksar, S.; Rouhollahpour, A.; Talesh, S. M. *J. Fluorine Chem.* **2012**, *141*, 11.
25. Habibi-Khorassani, S. M.; Hazeri, N.; Shahraki, M.; Abbasi, M.; Karima, M.; Ali, M. *Iran. J. Org. Chem.* **2013**, *5*, 1163.
26. Dekamin, M. G.; Eslami, M.; Maleki, A. *Tetrahedron* **2013**, *69*, 1074.
27. Qareaghaj, O. H.; Mashkouri, S.; Naimi-Jamal, M. R.; Kaupp, G.

RSC Adv. **2014**, *4*, 48191.

28. Safari, J.; Zarnegar, Z.; Heydarian, M. *Bull. Chem. Soc. Jpn.* **2012**, *85*, 1332.

29. Makarem, S.; Mohammadi, A. A.; Fakhari, A. R. *Tetrahedron Lett.* **2008**, *49*, 7194.

30. Kundu, S. K.; Mondal, J.; Bhaumik, A. *Dalton Trans.* **2013**, *42*, 10515.

31. Shekhar, A. C.; Kumar, A. R.; Sathaiah, G.; Raju, K.; Rao, P. S.; Sridhar, M.; Narsaiah, B.; Srinivas, P. V. S. S.; Sridhar, B. *Helv. Chim. Acta* **2012**, *95*, 502.

32. Al-Mousawi, S. M.; Elkholy, Y. M.; Mohammad, M. A.; Elnagdi, M. H. *Org. Prep. Proced. Int.* **1999**, *31*, 305.

33. Radwan, S. M.; Bakhite, E. A.; Kamal El-Dean, A. M. *Phosphorus*, *Sulfur Silicon Relat. Elem.* **1995**, *101*, 207.

34. Davoodnia, A.; Bakavoli, M.; Vahedinia, A.; Rahimizadeh, M.; Roshani, M. *Heterocycles* **2006**, *68*, 801.

35. Davoodnia, A.; Bakavoli, M.; Soleimany, M.; Tavakoli-Hoseini, N. *Monatsh. Chem.* **2009**, *140*, 355.

36. Davoodnia, A.; Bakavoli, M.; Moloudi, R.; Khashi, M.; Tavakoli-Hoseini, N. *Chin. Chem. Lett.* **2010**, *21*, 1-4.

37. Davoodnia, A.; Khashi, M.; Tavakoli-Hoseini, N.; Moloudi, R.; Zamani, H. A. *Monatsh. Chem.* **2013**, *144*, 677.

38. Khashi, M.; Davoodnia, A.; Chamani, J. *Phosphorus*, *Sulfur Silicon Relat. Elem.* **2014**, *189*, 839.

39. Bauer, A. W.; Kirby, W. M. M.; Sherris, J. C.; Turck, M. *Am. J. Clin. Pathol.* **1966**, *45*, 493.